Skip to main content
. 2020 Sep 24;123(12):1749–1756. doi: 10.1038/s41416-020-01087-x

Fig. 3. The synergistic effect of combined treatment with sunitinib and lonafarnib on the viability of 786-O and PNX0010 cells.

Fig. 3

a Effective doses (EDs) responses of 786-O and PNX0010 cells to sunitinib and lonafarnib. Cells were treated with either sunitinib or lonafarnib for 72 h. Cell viability was examined by CellTiter Blue assay. EDs (μM) were calculated using XLfit. b Combination drug-response curves for the sunitinib plus lonafarnib treatment. 786-O and PNX0010 cells were treated with various combinations of sunitinib and lonafarnib for 72 h. Cell viability was examined by CellTiter Blue assay. c The combination index (CI) for the sunitinib plus lonafarnib treatment. The CI was calculated using CalcuSyn 2.0 software as described in Materials and Methods. CI > 1.3: antagonism; CI 1.1–1.3: moderate antagonism; CI 0.9–1.1: additive effect; CI 0.8–0.9: slight synergism; CI 0.6–0.8: moderate synergism; CI 0.4–0.6: synergism; CI 0.2–0.4: strong synergism. d 786-O and PNX0010 cells were treated with sunitinib with or without lonafarnib (both at 10 μM) for 24 h. Apoptosis was examined using APO-BRDU kit followed by flow cytometry analysis. Data are presented as the mean ± S.D.